Literature DB >> 26590659

Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Peter Kosa1, Mika Komori2, Ryan Waters3, Tianxia Wu4, Irene Cortese5, Joan Ohayon6, Kaylan Fenton7, Jamie Cherup8, Tomas Gedeon9, Bibiana Bielekova10.   

Abstract

Understanding genotype-phenotype relationships or development/validation of biomarkers requires large multicenter cohorts integrated by universal quantification of crucial phenotypical traits, such as central nervous system (CNS) tissue destruction. We hypothesized that mathematical modeling-guided combination of biologically meaningful, semi-quantitative MRI elements characterized by high signal-to-noise ratio will provide such reliable, universal tool for measuring CNS tissue destruction. We retrospectively graded 15 elements in MRI scans performed in 419 untreated subjects with or without neurological diseases, while being blinded to their prospectively acquired clinical scores. We then used 305 subjects for disability-guided mathematical modeling to select and combine MRI elements that had non-redundant contributions to clinical disability, resulting in Combinatorial MRI Scale (COMRIS). We validated our model on the remaining 114 independent subjects. COMRIS requires 5-10 min per scan on average to compute and demonstrates highly significant (p < 0.0001) and validation-consistent Spearman correlation coefficients (0.75, 0.76, and 0.65) for the expanded disability status scale (EDSS), Scripps neurological rating scale (SNRS), and symbol digit modality test (SDMT) measures of neurological disability, respectively. Because COMRIS is not greatly influenced by MRI scanners or protocols and can be computed even in the presence of some motion artifacts, it does not require censoring out patients and it provides comparable results across different cohorts. As such, it represents a broadly available clinical and research tool that can facilitate multicenter research studies and comparative analyses across patient cohorts and research projects. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical disability; MRI; Multiple sclerosis

Mesh:

Year:  2015        PMID: 26590659      PMCID: PMC4656129          DOI: 10.1016/j.msard.2015.08.009

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  43 in total

Review 1.  T1 hypointensities and axonal loss.

Authors:  F Barkhof; G B Karas; M A van Walderveen
Journal:  Neuroimaging Clin N Am       Date:  2000-11       Impact factor: 2.264

2.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

Authors:  Maria Pia Sormani; Douglas L Arnold; Nicola De Stefano
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

3.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

4.  Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.

Authors:  R H C Lazeron; J B Boringa; M Schouten; B M J Uitdehaag; E Bergers; J Lindeboom; M I Eikelenboom; P H Scheltens; F Barkhof; C H Polman
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

5.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Authors:  Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Arch Neurol       Date:  2009-04

6.  Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.

Authors:  Rohit Bakshi; Mohit Neema; Brian C Healy; Zsuzsanna Liptak; Rebecca A Betensky; Guy J Buckle; Susan A Gauthier; James Stankiewicz; Dominik Meier; Svetlana Egorova; Ashish Arora; Zachary D Guss; Bonnie Glanz; Samia J Khoury; Charles R G Guttmann; Howard L Weiner
Journal:  Arch Neurol       Date:  2008-11

7.  T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study.

Authors:  M Sailer; N A Losseff; L Wang; M L Gawne-Cain; A J Thompson; D H Miller
Journal:  Eur J Neurol       Date:  2001-01       Impact factor: 6.089

8.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

9.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; G J M Parker; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

10.  Primary progressive multiple sclerosis: a 5-year clinical and MR study.

Authors:  G T Ingle; V L Stevenson; D H Miller; A J Thompson
Journal:  Brain       Date:  2003-08-05       Impact factor: 13.501

View more
  12 in total

Review 1.  Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Authors:  Bibiana Bielekova; Michael R Pranzatelli
Journal:  Semin Pediatr Neurol       Date:  2017-08-12       Impact factor: 1.636

2.  Genetic model of MS severity predicts future accumulation of disability.

Authors:  Kayla C Jackson; Katherine Sun; Christopher Barbour; Dena Hernandez; Peter Kosa; Makoto Tanigawa; Ann Marie Weideman; Bibiana Bielekova
Journal:  Ann Hum Genet       Date:  2019-08-08       Impact factor: 1.670

3.  Drug library screen identifies inhibitors of toxic astrogliosis.

Authors:  Ruturaj Masvekar; Peter Kosa; Christopher Barbour; Joshua L Milstein; Bibiana Bielekova
Journal:  Mult Scler Relat Disord       Date:  2022-01-04       Impact factor: 4.339

4.  An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.

Authors:  Gloria Kim; Shahamat Tauhid; Sheena L Dupuy; Subhash Tummala; Fariha Khalid; Brian C Healy; Rohit Bakshi
Journal:  J Neurol       Date:  2016-01-11       Impact factor: 4.849

5.  New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.

Authors:  Ann Marie Weideman; Christopher Barbour; Marco Aurelio Tapia-Maltos; Tan Tran; Kayla Jackson; Peter Kosa; Mika Komori; Alison Wichman; Kory Johnson; Mark Greenwood; Bibiana Bielekova
Journal:  Front Neurol       Date:  2017-11-10       Impact factor: 4.003

6.  Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis.

Authors:  Ruturaj Masvekar; Jordan Mizrahi; John Park; Peter R Williamson; Bibiana Bielekova
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

7.  HIV-Negative Cryptococcal Meningoencephalitis Results in a Persistent Frontal-Subcortical Syndrome.

Authors:  Katherine Traino; Joseph Snow; Lillian Ham; Angela Summers; Laura Segalà; Talia Shirazi; Nadia Biassou; Anil Panackal; Seher Anjum; Kieren A Marr; William C Kreisl; John E Bennett; Peter R Williamson
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

8.  The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.

Authors:  Fawad Yousuf; Gloria Kim; Shahamat Tauhid; Bonnie I Glanz; Renxin Chu; Subhash Tummala; Brian C Healy; Rohit Bakshi
Journal:  Front Neurol       Date:  2016-06-29       Impact factor: 4.003

9.  Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.

Authors:  Jason Stein; Quangang Xu; Kayla C Jackson; Elena Romm; Simone C Wuest; Peter Kosa; Tianxia Wu; Bibiana Bielekova
Journal:  Front Neurol       Date:  2018-07-20       Impact factor: 4.003

10.  NeurEx: digitalized neurological examination offers a novel high-resolution disability scale.

Authors:  Peter Kosa; Christopher Barbour; Alison Wichman; Mary Sandford; Mark Greenwood; Bibiana Bielekova
Journal:  Ann Clin Transl Neurol       Date:  2018-09-24       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.